Arven Pharmaceuticals Information

Arven started to develop inhalation products and biologics in 2007. Main goal of the company is to focus on specific product areas and -difficult to make- products. Taking into account the rapidly changing dynamics of global regulatory environment, Toksoz Group decided to start up Arven dedicated only to development and manufacture of inhalation products and biologics. To support this vision, Arven established teams of highly qualified and dedicated research scientists, as well as build a brand new 28,000 square meter manufacturing facility located in the Kirklareli, Turkey. Arven strives for developing products for global market, with strategy of “One Product Globally”. Arven is the first Turkish company developing a biosimilar for global markets, including USA and EU Development of biosimilars are carried out according to international guidelines and regulations including WHO, ICH, FDA and EMA Arven’s expertise includes: • Production of therapeutic proteins • Determination of Quality of therapeutic proteins • Head to head comparison with reference products • Analytical similarity studies • Bioassay studies • Receptor binding studies and others ARVEN is growing with the motto "We design technology for the future and we provide future for human health"